In-vitro and in-vivo activities of DW-116, a new fluoroquinolone

DW-116 is a novel fluoroquinolone that was two- to four-fold more active than rufloxacin and less active than sparfloxacin, ciprofloxacin and ofloxacin against Gram-positive bacteria in vitro. Against Gram-positive and Gram-negative bacteria, the in-vivo activity of DW-116 was similar or slightly gr...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 39; no. 4; pp. 509 - 514
Main Authors CHOIA, K.-H, HONG, J.-S, KIM, S.-K, LEE, D.-K, YOON, S.-J, CHOI, E.-C
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.04.1997
Subjects
Animals
Anti-Infective Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - prevention & control
Biological and medical sciences
Ciprofloxacin - pharmacology
Dose-Response Relationship, Drug
Enterococcus faecalis - drug effects
Fluoroquinolones
Gram-Negative Bacteria - drug effects
Gram-Positive Bacteria - drug effects
Male
Medical sciences
Methicillin Resistance
Mice
Mice, Inbred ICR
Microbial Sensitivity Tests
Ofloxacin - pharmacology
Pharmacology. Drug treatments
Piperazines - pharmacology
Pseudomonas aeruginosa - drug effects
Quinolones - pharmacology
Staphylococcus aureus - drug effects
Drug susceptibility test
Rodentia
Oral administration
In vitro
Biological activity
Infection
Resistance
In vivo
Vertebrata
Antibiotic
Chemotherapy
Fluoroquinolone derivatives
Mammalia
Treatment
Mouse
Gram positive bacteria
Animal
Bacteriosis
Effective dose
Activity spectrum
Antibacterial agent
Comparative study
Gram negative bacteria
Online AccessGet full text

Cover

More Information
Summary:DW-116 is a novel fluoroquinolone that was two- to four-fold more active than rufloxacin and less active than sparfloxacin, ciprofloxacin and ofloxacin against Gram-positive bacteria in vitro. Against Gram-positive and Gram-negative bacteria, the in-vivo activity of DW-116 was similar or slightly greater than that of rufloxacin and less than that of sparfloxacin, ciprofloxacin and ofloxacin. ED50 (50% effective dose) values for DW-116 did not correlate with in-vitro MICs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/39.4.509